RESUMO
No disponible
Assuntos
Masculino , Humanos , Fístula Traqueoesofágica/etiologia , Intubação Intratraqueal/efeitos adversos , Traumatismo Múltiplo/complicações , Fatores de RiscoRESUMO
No disponible
Assuntos
Feminino , Pessoa de Meia-Idade , Humanos , Pneumatose Cistoide Intestinal/diagnóstico , Colo/patologia , ColonoscopiaAssuntos
Colestase Intra-Hepática/etiologia , Ductos Biliares Intra-Hepáticos/diagnóstico por imagem , Ductos Biliares Intra-Hepáticos/patologia , Colestase Intra-Hepática/diagnóstico , Colestase Intra-Hepática/terapia , Feminino , Humanos , Testes de Função Hepática , Pessoa de Meia-Idade , RadiografiaRESUMO
No disponible
Assuntos
Feminino , Pessoa de Meia-Idade , Humanos , Ductos Biliares Intra-Hepáticos , Colagogos e Coleréticos/uso terapêutico , Omeprazol/uso terapêutico , Inibidores Enzimáticos/uso terapêutico , Doenças dos Ductos Biliares/diagnóstico , Doenças dos Ductos Biliares/tratamento farmacológico , Ácido Ursodesoxicólico/uso terapêuticoRESUMO
No disponible
Assuntos
Feminino , Pessoa de Meia-Idade , Humanos , Ductos Biliares Intra-Hepáticos , Colagogos e Coleréticos/uso terapêutico , Omeprazol/uso terapêutico , Inibidores Enzimáticos/uso terapêutico , Doenças dos Ductos Biliares/diagnóstico , Doenças dos Ductos Biliares/tratamento farmacológico , Ácido Ursodesoxicólico/uso terapêuticoRESUMO
No disponible
Assuntos
Feminino , Idoso , Humanos , Cistadenocarcinoma Mucinoso/diagnóstico , Neoplasias do Apêndice/diagnóstico , Biópsia , ColonoscopiaRESUMO
No disponible
Assuntos
Humanos , Masculino , Adulto , Antibacterianos , Clindamicina , Doenças do Esôfago , ÚlceraAssuntos
Degeneração Hepatolenticular , Complicações na Gravidez , Adolescente , Ensaios Enzimáticos Clínicos , Feminino , Degeneração Hepatolenticular/diagnóstico , Degeneração Hepatolenticular/tratamento farmacológico , Humanos , Testes de Função Hepática , Gravidez , Complicações na Gravidez/diagnóstico , Complicações na Gravidez/tratamento farmacológico , Transaminases/sangue , Sulfato de Zinco/administração & dosagem , Sulfato de Zinco/uso terapêuticoRESUMO
No disponible
Assuntos
Gravidez , Adolescente , Feminino , Humanos , Complicações na Gravidez , Degeneração Hepatolenticular , Sulfato de Zinco , Transaminases , Testes de Função Hepática , Ensaios Enzimáticos ClínicosRESUMO
No disponible
Assuntos
Idoso , Masculino , Humanos , Actinomyces , Abscesso Hepático , Testes de Função HepáticaRESUMO
Dieulafoy's lesion is a vascular anomaly generally located in the proximal stomach, although it has also been documented in other areas such as the colorectum. It is mainly found in men aged between 50 and 70 years, and represents less than 2% of acute gastrointestinal hemorrhagic episodes.A 66-year-old woman who was undergoing oral Diclofenac treatment presented with black stools. Endoscopy revealed acute duodenal erosions with no signs of bleeding. Black stools persisted after Diclofenac was discontinued and omeprazole treatment was started and the patient was admitted to hospital after 7 days. Colonoscopy revealed active bleeding in the upper colon, which ceased after sclerosis with ethanolamine oleate. The patient was discharged from hospital but was readmitted 10 days later because of rebleeding. The results of upper endoscopy were normal and colonoscopy performed 3 days later detected neither lesions nor bleeding. The pathogenesis of Dieulafoy's lesion is not well known, although it could be caused by erosion of the mucous lining of a vessel. Definitive diagnosis is histologic, although certain endoscopic diagnostic signs have been described. Endoscopic diagnosis is sometimes difficult; in such cases, arteriography should be employed, both for diagnostic and therapeutic purposes. The treatment of choice is endoscopic and the use of two hemostatic methods is advisable. If these procedures fail, surgery is required. Arteriography is the most suitable alternative in patients who are poor candidates for surgery.
Assuntos
Doenças do Colo/complicações , Hemorragia Gastrointestinal/etiologia , Doenças Vasculares Periféricas/complicações , Idoso , Feminino , HumanosAssuntos
Transplante de Medula Óssea/imunologia , Gastrite/diagnóstico , Gastroscopia/métodos , Herpes Zoster/diagnóstico , Hospedeiro Imunocomprometido , Leucemia Promielocítica Aguda/terapia , Aciclovir/uso terapêutico , Adulto , Feminino , Seguimentos , Mucosa Gástrica/virologia , Gastrite/tratamento farmacológico , Gastrite/imunologia , Gastrite/virologia , Herpes Zoster/tratamento farmacológico , Herpes Zoster/imunologia , Humanos , Leucemia Promielocítica Aguda/imunologia , Medição de Risco , Resultado do TratamentoRESUMO
OBJECT: To evaluate the effectiveness of Ranitidine i.v. versus Omeprazole i.v. for gastrointestinal bleeding of peptic origin. MATERIAL AND METHODS: Prospective, comparative, randomized and open study of 81 in-patients, hospitalized consecutively during 13 months, with gastrointestinal bleeding of peptic origin and signs of recent hemostasis (S.R.H.), belonging to the groups Forrest Ib and II. Treatment groups: group A: Ranitidine: initial injection of 50 mg. i.v., followed by 100 mg/6 hours i.v., during the first 72 hours and afterwards by 150 mg/12 hours, orally; group B: Omeprazole: initial injection of 80 mg. i.v., followed by 40 mg/8 hours i.v. during the first 72 hours and afterwards by 20 mg/24 hours, orally. Evaluation criteria: persistent haematemesis and melena; need for transfusions: treatment failure average period of hospitalization and disappearance of S.R.H. after 72 hours. RESULTS: 43 patients received Ranitidine and 38 Omeprazole. Both groups were homogeneous in regard to variables ar hospitalization. No significant differences were found between these two groups: persistent melena (26% group A vs. 8% group B); patients who needed transfusion (39% vs. 31%); treatment failure (19% vs. 5%); average period of hospitalization; and disappearance of S.R.H. (81% vs. 95%). None of the patients died. CONCLUSIONS: The effectiveness of Ranitidine i.v. and Omeprazole i.v., in the dosage used and in a selected group of patients with gastrointestinal bleeding, is similar. However, there is a trend to register less treatment failures and a higher percentage of S.R.H. disappearance with the patients treated with Omeprazole. Further studies with more patients are necessary to confirm this tendency.